Viking Therapeutics, Inc
VKTXViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for metabolic and endocrine disorders. The company utilizes its proprietary platform to advance novel treatments targeting liver and metabolic diseases, as well as rare genetic disorders.
Company News
Viking Therapeutics announced that CEO Brian Lian will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12-15, 2026, in San Francisco. The presentation is scheduled for 2:15-2:55 p.m. Pacific on Monday, January 12, with a live webcast available. Viking is a clinical-stage biopharmaceutical company developing therapies for m...
Viking Therapeutics, a biotech company with an oral anti-obesity drug VK2735, is potentially a takeover target in 2026 due to its promising drug pipeline despite some initial safety concerns in clinical trials.
Viking Therapeutics, a clinical-stage biopharmaceutical company, is showing promise with its injectable weight loss treatment VK2735 in Phase 3 trials. Despite being pre-revenue, the stock has risen over 36% in three months, with analysts projecting significant potential in the growing GLP-1 market.
Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesi...
Eli Lilly and Novo Nordisk have created the biggest ever pharmaceutical market with its miraculous weight loss drugs. Read more on LLY stock here.
